Oslo, March 2, 2023: Attention is drawn to Targovax ASA’s (“Targovax” or the “Company”) stock exchange announcement (“Targovax” or the “Company”) published on March 2, 2023 in relation to the decision of the Board of Directors to increase the share capital of the Company by issuance at 10,378 NOK.90 of 103,789 new shares with a nominal value of NOK 0.10 each to facilitate the exercise of 103,789 RSUs under the Company’s RSU program for board members.
Chief Insider Diane Mellett, Member of the Board of Directors, has exercised 20,870 Restrictive Stock Units (“RSUs”) under her RSU Agreement and has subscribed for 20,870 new shares of the Company following the exercise of RSUs. The exercise price for the options was NOK 0.10 per new share.
Primary Insider, Robert Burns, Member of the Board of Directors, exercised 23,307 Restrictive Stock Units (“RSUs”) under his RSU Agreement and subscribed for 23,307 new shares of the Company following the exercise of RSUs. The exercise price for the options was NOK 0.10 per new share.
Primary Insider Damian Marron, Member of the Board of Directors, exercised 55,588 Restrictive Stock Units (“RSUs”) under his RSU Agreement and subscribed for 55,588 new shares of the Company following the exercise of RSUs. The exercise price for the options was NOK 0.10 per new share.
The primary insider, Eva-Lotta Allan, a member of the Board of Directors, exercised 4,024 Restrictive Stock Units (“RSUs”) under her RSU agreement and, following the exercise of the RSUs, subscribed for 4,024 new shares of the Company. The exercise price for the options was NOK 0.10 per new share.
Following the RSU exercise and subscription for new shares and the registration of the share capital increase in respect of the new shares with the Norwegian Company Register (Nw. Foretaksregisteret), the above primary insiders hold the following:
Diane Mellett holds 122,948 shares, 104,388 RSUs and zero options in Targovax.
Robert Burns holds 298,761 shares, 43,071 RSUs and zero options in Targovax.
Damian Marron holds 55,588 shares, 97,765 RSUs and zero options in Targovax.
Eva-Lotta Allan holds 98,883 shares, 64,469 RSUs and zero options in Targovax.
Please refer to the attached trade announcement for further details.
Notification of Primary Insiders 02.03.23.docx.pdf
For more information please contact:
Erik Digman Wiklund, CEO
Telephone: +47 413 33 536
Email: [email protected]
Renate Birkeli, Investor Relations
Telephone: +47 922 61 624
Email: [email protected]
Media Inquiries:
Andreas Tinglum – Corporate Communications (Norway)
Telephone: +47 9300 1773
Email: [email protected]
About Targovax
Activation of the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical-stage immuno-oncology company developing immune activators that target hard-to-treat solid tumors. Targovax is focused on activating the patient’s immune system to fight cancer and helping cancer patients with few treatment alternatives available. Targovax is developing its product candidates in multiple cancer indications, including melanoma, mesothelioma, multiple myeloma and pancreatic cancer.
Targovax’s lead clinical candidate, ONCOS-102, is a genetically engineered oncolytic adenovirus designed to selectively infect cancer cells and activate the immune system against the tumor. ONCOS-102 has demonstrated a favorable efficacy, immune and safety profile in multiple indications, both as monotherapy and in combination, and ONCOS-102 is in a randomized Phase 2 study in melanoma patients refractory to treatment with PD -1 checkpoint inhibitors are resistant.
Targovax has also established a state-of-the-art circular RNA program (circRNA) with the intent to develop next-generation RNA therapeutics for various applications, building on clinical experience and deep mechanistic insights from its first-generation products. In addition, Targovax has a KRAS immunotherapy program with lead candidate TG01 set to enter clinical trials in early 2023 in an expanded format in pancreatic cancer and multiple myeloma. This provides Targovax with a rich pipeline of innovative future therapeutic candidates to follow ONCOS-102.
https://news.cision.com/targovax/r/targovax-asa–mandatory-notification-of-trade-by-primary-insiders-pertaining-to-rsus,c3726627
https://mb.cision.com/Public/17093/3726627/8ed179f09261c940.pdf
(c) Decision 2023. All rights reserved., Source press releases – English
